DrugPatentWatch Database Preview
Drugs in Development Information for Hypericin
» See Plans and Pricing
What is the development status for investigational drug Hypericin?
Hypericin is an investigational drug.
There have been 5 clinical trials for Hypericin.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are HIV Infections, Lymphoma, T-Cell, Cutaneous, and Lymphoma, T-Cell. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), VIMRx Pharmaceuticals, and St Stephens Aids Trust.
There are two US patents protecting this investigational drug and fourteen international patents.
Summary for Hypericin
| US Patents | 2,000 |
| International Patents | 14,024 |
| US Patent Applications | 3,496 |
| WIPO Patent Applications | 2,061 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 1 (2016-10-01) |
| Vendors | 64 |
Recent Clinical Trials for Hypericin
| Title | Sponsor | Phase |
|---|---|---|
| Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis | University Hospital Tuebingen | Phase 3 |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | Soligenix | Phase 3 |
| Boceprevir and Ucalm (St John&Apos;s Wort) | University of Liverpool | Phase 1 |
Clinical Trial Summary for Hypericin
Top disease conditions for Hypericin
Top clinical trial sponsors for Hypericin
US Patents for Hypericin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Hypericin | Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | Start Trial |
| Hypericin | Start Trial | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| Hypericin | Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | Start Trial |
| Hypericin | Start Trial | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Hypericin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Hypericin | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | Start Trial |
| Hypericin | Australia | AU2011210567 | 2030-01-29 | Start Trial |
| Hypericin | Canada | CA2787784 | 2030-01-29 | Start Trial |
| Hypericin | European Patent Office | EP2528893 | 2030-01-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
